Savings Program

Invivyd Patient Savings Program

Not an actual patient.

You can now access financial assistance for PEMGARDA™

We understand the cost of medicines may be a concern for many patients. Enroll in the Invivyd Patient Savings Program today and learn more about available financial assistance.

  • PEMGARDA has not been approved, but has been authorized for emergency use by FDA under an EUA, for pre-exposure prophylaxis of COVID-19 in certain adults and adolescent individuals (12 years of age and older weighing at least 40 kg); and
  • The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization revoked sooner.

There are 2 ways you can enroll:

  • 1 Call 888-550-4883 between 8:30 AM–8:00 PM ET Monday through Friday
  • 2 Sign up by following the instructions on the Invivyd Patient Savings Portal

Once you are enrolled, you can submit a claim through the portal or mail:

  • 1 To submit a claim via the portal, you will need:
    • To create an Invivyd Patient Savings Portal account at https://invivyd.patientsavings.com
    • Your insurance information
    • Information to verify your drug purchase (eg, explanation of benefits from insurance carrier)
  • 2 To submit a claim via mail,* you will need:
    • Invivyd Patient Savings Program Reimbursement Form (available on the portal)
    • Information to verify your drug purchase (eg, explanation of benefits from insurance carrier)

Please note: You may only submit a claim if you have commercial insurance and you are not a participant of Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Civilian Health and Medical Program of the Uniformed Services (CHAMPUS), TRICARE®, or other federal or state program.

Eligibility Requirements

Program participation is limited to patients who are eligible to be prescribed PEMGARDA. Patient must have been prescribed PEMGARDA for pre-exposure prophylaxis to help prevent COVID-19 at the time the prescription is filled and administered to the patient. Patient must have commercial health insurance that provides coverage for some portion of the cost of PEMGARDA.

Complete Terms and Conditions

INVIVYD Savings Program Eligibility Criteria, Terms, and Conditions

Program: This savings assistance program is offered by Invivyd, Inc. (“Invivyd”) to support eligible patients who have been prescribed PEMGARDA (pemivibart) and have commercial insurance covering PEMGARDA. PEMGARDA is an investigational medicine that is authorized for use for pre-exposure prophylaxis to help prevent COVID-19 in certain adults and adolescents 12 years of age and older who otherwise meet the eligibility criteria to be prescribed PEMGARDA.

Terms and Conditions: By using the PEMGARDA Savings Program (hereafter, the “Program”), the patient acknowledges that they understand, currently meet, and will comply with all the Terms and Conditions listed below as a condition of their participation in the Program.

Use of Program Data: Data related to patient participation in the Program may be collected, analyzed, and shared with Invivyd, for market research and other purposes related to assessing Invivyd’s patient support programs. Data shared with Invivyd will be aggregated and de-identified and will not identify the patient.

Patient Eligibility Requirements: Program participation is limited to patients who are eligible to be prescribed PEMGARDA. Patient must have been prescribed PEMGARDA for pre-exposure prophylaxis to help prevent COVID-19 at the time the prescription is filled and administered to the patient. Patient must have commercial health insurance that provides coverage for some portion of the cost of PEMGARDA.

Program Restrictions: Program participation is limited to residents of the United States, Puerto Rico, and U.S. territories. Cash-paying patients are not eligible to participate in the Program. Use of the Program is not permitted for prescriptions reimbursed under Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD), Civilian Health and Medical Program of the Uniformed Services (CHAMPUS), TRICARE®, or other federal or state health programs (such as medical assistance programs). Cash discount cards and other non-insurance plans may not be used in connection with this Program. If the patient is eligible for drug benefits under any of the above listed programs, the patient cannot participate in this Program. By participating in the Program, the patient certifies that they will comply with any requirements of their insurance provider to notify the insurance provider of the existence and/or value of the Program. The patient should not participate in the Program if their insurer or health plan prohibits use of manufacturer savings assistance. It is illegal to (or offer to) sell, purchase, or trade any benefit offered under this Program. The savings are not transferable and are limited to 4 uses per calendar year. Void where prohibited by law. Program managed by IQVIA on behalf of Invivyd.

Program Terms: Invivyd reserves the right to rescind, revoke or amend the terms of this Program without notice at any time.

To the Patient: To access the Savings Card, you must be 12 years of age or older and have a valid prescription for PEMGARDA for pre-exposure prophylaxis to help prevent COVID-19. Follow the dosage instructions given by your doctor. The Savings Card may not be redeemed for cash. By using the Savings Card, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described herein. The Program is not health insurance and is not conditioned on any past or future purchases. Patients with questions about the Program should call 888-550-4883.

To the Provider or Pharmacist: When you apply the Savings Card to a patient’s prescription, you are certifying that you have (i) not submitted, and will not submit, a claim for reimbursement under any federal, state, or other governmental programs for the prescription, and have (ii) confirmed the patient is 12 years of age or older and have been prescribed PEMGARDA (pemivibart) for pre-exposure prophylaxis of COVID-19. Your participation in this Program must comply with all applicable laws and regulations as a healthcare provider. By participating in this Program, you are certifying that you will comply with the Terms and Conditions described herein.

Patient Consent to Allow Savings Program Payment to Healthcare Provider: The Patient, or the Legal Guardian of the Patient, authorizes the Invivyd Patient Savings Program (hereafter, the “Program”) to:

  • Provide payment directly to the healthcare provider, and not the patient, for out-of-pocket drug cost when the healthcare provider submits the copay claim.
  • Allow the healthcare provider to contact the Program on the Patient’s behalf to initiate payment for services after they have been rendered.
  • Understands that they will be responsible for any out-of-pocket expenses for PEMGARDA if (1) the healthcare provider does not request payment within 180 days from the date of service, or (2) if they are deemed ineligible for reimbursement from the Program.

The Patient understands the above information and gives consent for the healthcare provider to submit and receive payment claims at their direction.

Note: If your healthcare provider is willing to submit your copay claims on your behalf and you wish them to do so, please provide them with your copay identifier information. Your healthcare provider cannot conduct any activity on your behalf unless you direct them to do so and provide your copay identifier information.

The Patient, or the Legal Guardian of the Patient, hereby attests to the following:

  • 1 Commercial Insurance: They have commercial health insurance in effect and will utilize this insurance as the primary payer for my healthcare expenses.
  • 2 No Government Insurance: They are not currently enrolled in any government insurance programs, including Medicare, Medicaid, Medigap, VA, DoD, CHAMPUS, TRICARE®, or other federal or state health programs.
  • 3 Copay Program Eligibility: They understand that this copay program is intended to supplement, not replace, their existing commercial insurance coverage.
  • 4 Accurate Information: They certify that the information provided in this attestation is true and accurate to the best of their knowledge.

Please note: Misrepresenting insurance coverage may result in ineligibility for the Invivyd Savings Program. Invivyd understands that your personal and health information is private and will only use your information in accordance with our Privacy Policy found at https://invivyd.com/privacy. The information you provide will only be used by Invivyd and parties acting on its behalf to send you the materials you requested as well as other helpful products and/or related product information, disease state information, offers, and services.

The Patient, or the Legal Guardian of the Patient, has read and acknowledged the above privacy statement.

The Patient attests to having 1 of the following medical conditions:

  • Active treatment for solid tumor and hematologic malignancies.
  • Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia).
  • Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy.
  • Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy).
  • Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome).
  • Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV).
  • Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents).

The Patient, or as the Legal Guardian of the Patient, agrees to receive communications from Invivyd, the Invivyd Patient Savings Program and/or parties acting on Invivyd’s behalf to determine eligibility and provide benefits verification, prior authorization/appeals assistance, and financial assistance resources and information, such as copay assistance, and for other non-marketing purposes such as, but not limited to, medication updates and dosing reminders.

  • The Patient, or as the Legal Guardian of the Patient, agrees to be contacted by Invivyd, the Invivyd Patient Savings Program, or parties working on Invivyd’s behalf for these purposes through email or by using an autodialer or prerecorded voice at the telephone number(s) provided.
  • If the Patient is an eligible minor or an adult under the care of a guardian, they have also agreed to receive such communications from Invivyd, the Invivyd Patient Savings Program, and/or parties acting on their behalf for the purposes described above, and hereby give permission for Invivyd, the Invivyd Patient Savings Program, and/or parties acting on their behalf to contact the caregiver or guardian for such purposes.
  • The Patient, or as the Legal Guardian of the Patient, understands that they (and, if applicable, my caregiver) can opt out of these communications at any time by contacting Invivyd Patient Savings Program, 888-550-4883.
  • The Patient, or as the Legal Guardian of the Patient, agrees to receive communications described above.

*Mailing address available upon enrollment from the portal or call center (888-550-4883).

Important Safety Information Expand

What is the most important information I should know about PEMGARDA?

PEMGARDA may cause serious side effects, including:

  • A serious allergic reaction called anaphylaxis. Anaphylaxis can be life-threatening and can happen during or after your infusion of PEMGARDA. In case you have a severe allergic reaction to PEMGARDA and need medical help right away, you will receive PEMGARDA in a healthcare setting. Your healthcare provider will monitor you for allergic reactions during your infusion and for at least 2 hours after you are finished receiving PEMGARDA. Your healthcare provider will stop PEMGARDA right away if you develop signs or symptoms of anaphylaxis or severe allergic reaction. Tell your healthcare provider right away if you get any of the following signs or symptoms of anaphylaxis during or after your infusion of PEMGARDA:
  • itching
  • flushing
  • hives
  • skin redness
  • swelling of your face, lips, mouth, tongue, throat, hands, or feet
  • sweating
  • dizziness
  • ringing in the ears
  • wheezing
  • trouble breathing
  • chest discomfort
  • fast heartbeat

What should I tell my healthcare provider before I receive PEMGARDA?

Tell your healthcare provider about all of your medical conditions, including if you:

  • have any allergies, including if you have had a severe allergic reaction to a COVID-19 vaccine or PEMGARDA.
  • are pregnant or plan to become pregnant. It is not known if PEMGARDA can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if PEMGARDA can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive PEMGARDA.
  • have any serious illnesses.
  • take any medicines, including prescription, over-the-counter, vitamins, and herbal products.

Who should generally not take PEMGARDA?

Do not take PEMGARDA if you have had a severe allergic reaction to PEMGARDA or any ingredient in PEMGARDA.

What are the important possible side effects of PEMGARDA?

  • See “What is the most important information I should know about PEMGARDA?”
  • Allergic and infusion-related reactions: Allergic and infusion-related reactions are common and can sometimes be severe or life-threatening. Allergic and infusion-related reactions can happen during and after your infusion of PEMGARDA. You may have an increased risk of allergic reaction with PEMGARDA if you have had a severe allergic reaction to a COVID-19 vaccine.

Tell your healthcare provider right away if you get any of the following signs and symptoms of an allergic or infusion-related reaction during or after your infusion of PEMGARDA:

  • fever
  • trouble breathing or shortness of breath
  • chills
  • tiredness
  • fast or slow heart rate
  • chest pain or discomfort
  • weakness
  • confusion
  • nausea
  • headache
  • throat tightness or irritation
  • high or low blood pressure
  • swelling of your face, lips, mouth, tongue, throat, hands, or feet
  • rash, including hives
  • itching
  • muscle aches
  • feeling lightheaded, faint, or dizzy
  • sweating

The side effects of receiving any medicine by vein (IV) may include pain, redness, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.

The most common side effects in people treated with PEMGARDA who have moderate-to-severe immune compromise include allergic and infusion-related reactions, infusion site reactions, common cold, viral infection, flu-like illness, tiredness, headache, and nausea.

These are not all the possible side effects of PEMGARDA. Not a lot of people have been given PEMGARDA. Serious and unexpected side effects may happen. PEMGARDA is still being studied, so it is possible that all of the risks are not known at this time.

What other important information do I need to know when receiving PEMGARDA?

Risk of COVID-19 caused by certain SARS-CoV-2 variants: Viruses can change over time (mutate) and develop into a slightly different form of the virus, called a variant. PEMGARDA may not prevent COVID-19 caused by certain SARS-CoV-2 variants. If you are exposed to these variants, your chance of developing COVID-19 is higher than from other variants. Tell your healthcare provider right away, and test for COVID-19, if you develop any symptoms of COVID-19, including:

  • fever or chills
  • cough
  • shortness of breath or difficulty breathing
  • congestion or runny nose
  • nausea or vomiting
  • diarrhea
  • headache
  • sore throat
  • new loss of taste or smell
  • feeling tired (fatigue)
  • muscle or body aches

For more information about the symptoms of COVID-19, go to https://www.cdc.gov/covid/signs-symptoms/.

If you develop COVID-19, your healthcare provider may recommend one of the available COVID-19 treatments.

How do I report side effects with PEMGARDA?

Tell your healthcare provider right away if you have any side effect that bothers you or does not go away. Report side effects to FDA MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088 or call Invivyd at 1-800-890-3385.

Please read the accompanying Fact Sheet for Patients, Parents and Caregivers for more information.